NCT02896205View on ClinicalTrials.gov

Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

July 1, 2017

Study Completion Date

July 1, 2017

Conditions
Systemic SclerosisSclerodermaInterstitial Lung Disease
Interventions
DRUG

Mycophenolate mofetil

Subjects will be given oral Mycophenolate Mofetil starting at 500mg twice a day and increased gradually to a target dose of 2gram per day for 6 months

DRUG

Placebo

Subjects will be given matching placebo for 6 months

Trial Locations (1)

160012

PGIMER, Chandigarh

All Listed Sponsors
lead

Post Graduate Institute of Medical Education and Research, Chandigarh

OTHER

NCT02896205 - Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease | Biotech Hunter | Biotech Hunter